Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-28 18:20:34 - browse：554

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

WSS

Thousands of Marines and sailors deploy to Middle East to deter Iran from seizing ships

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

The UK government moves asylum

Medicare Advantage proposed rates disappoint insurers

Key House Republican on health care plans exit from Congress

focus

Wikipedia

hotspot

Virginia high school admissions case could be legal follow

Vaccine advisory panel ACIP left half staffed by HHS

United colonoscopy coverage change 'may cost lives,' doctors say

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The UK government moves asylum

United colonoscopy coverage change 'may cost lives,' doctors say

Why did Pfizer dish out millions for a Super Bowl ad?

Medicare proposal to cover medical devices draws a mixed reaction

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

focus

Key House Republican on health care plans exit from Congress

Key House Republican on health care plans exit from Congress

South Korea begins evacuating thousands of Scouts from coastal campsite as tropical storm nears

Why workplace violence is so common in health care

Moderna hits safety problems in bold bid to reinvent medicine

The UK government moves asylum

explore

focus

hotspot

leisure time